Annual report pursuant to Section 13 and 15(d)

LIQUIDITY (Details)

v3.23.2
LIQUIDITY (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Jan. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Accumulated deficit   $ (260,985) $ (209,198)
Net loss   (51,787) (41,060)
Net cash used in operating activities   (44,481) (39,616)
Cash and cash equivalents   16,036 150,410
Short-term investments in marketable debt securities   85,860  
Long-term investments in marketable debt securities   16,470  
Total liabilities   7,549 2,949
Current liabilities   5,200 $ 2,462
XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 | Xoma License Agreement | Plan      
Milestone closing payment $ 5,000 $ 5,000